Clinical Trials

Alexey Danilov, Assistant Professor, Molecular Therapeutics
  • NCI
    A dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities and/or renal dysfunction
Marc Ernstoff, Professor, Immunology and Cancer Immunotherapy
  • Hoffman LaRoche
    A Phase III, double-blind, placebo-controlled study of vemurafenib versus vemurafenib plus GDC-0973 in previously untreated brafv600-mutation positive patients with unresectable locally advanced or metastatic melanoma
Frederick Lansigan, Assistant Professor, Molecular Therapeutics
  • Kyowa Hakko Kirin Pharmaceutical, Inc
    Open-label, multi-center, randomized study of anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) versus vorinostat in subjects with previously treated cutaneous T-cell lymphoma
James Rigas, Associate Professor, Molecular Therapeutics
  • Bristol Myers Squibb
    An open-label randomized Phase III trial of BMS-936558 versus docetaxel in previously treated advanced or metastatic non-squamous Non-Small Cell Lung Cancer (NSCLC)